Tubulosine selectively inhibits JAK3 signalling by binding to the ATP‐binding site of the kinase of JAK3

Gain‐ or loss‐of‐function mutations in Janus kinase 3 (JAK3) contribute to the pathogenesis of various haematopoietic malignancies and immune disorders, suggesting that aberrant JAK3 signalling is an attractive therapeutic target to treat these disorders. In this study, we performed structure‐based...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Byung‐Hak, Yi, Eun Hee, Jee, Jun‐Goo, Jeong, Ae Jin, Sandoval, Claudio, Park, In‐Chul, Baeg, Gyeong Hun, Ye, Sang‐Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339168/
https://www.ncbi.nlm.nih.gov/pubmed/32558259
http://dx.doi.org/10.1111/jcmm.15362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339168/
https://www.ncbi.nlm.nih.gov/pubmed/32558259
http://dx.doi.org/10.1111/jcmm.15362

Ejemplares similares